semaglutide 7.2 mg clinical trial week 7 Once-weekly 7·2 in adults with obesity (STEP UP): a randomised, controlled, phase 3b How long after taking semaglutide – STEP UP: Semaglutide 7.2mg achieves

The most common concern involves gastrointestinal adverse effects, which are already the most frequently reported side effects of GLP-1 receptor agonists

Microdosing semaglutide, using doses below the standard therapeutic range, has gained attention as an approach for people who want modest appetite suppression with minimal side effects

Patients with certain genetic predispositions may achieve appetite control faster or experience earlier onset nausea, altering whether morning or evening injection timing is tolerated better

Blood Sugar Levels: Monitoring blood glucose levels is crucial, especially for those with diabetes, as high blood sugar can affect heart function

Reduced Side Effects: Gastrointestinal problems, such as nausea, vomiting, diarrhea, and constipation, are less common at higher doses